Clinical study| Volume 114, ISSUE 6, P463-469, April 15, 2003

Download started.


Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse



      To determine the relapse rate and outcome in patients with Wegener’s granulomatosis treated with daily cyclophosphamide and glucocorticoids to induce remission followed by methotrexate for remission maintenance.


      We performed an open-label prospective study in 42 patients with active Wegener’s granulomatosis. All patients were treated with a standardized regimen. Outcomes were assessed using predetermined definitions based on clinical characteristics and pathologic, laboratory, and radiographic findings.


      All patients achieved disease remission. The median time to remission was 3 months, and the median time to discontinuation of glucocorticoids was 8 months. During a median of 32 months of follow-up, 1 patient died (of a myocardial infarction not related to vasculitis). Two patients (5%) had to withdraw from the study because of medication toxicity. Twenty-two patients (52%) relapsed, with glomerulonephritis occurring in 16 patients. Of these 16 patients, 4 had an increase of >0.2 mg/dL in serum creatinine level. All 4 patients returned to their prior level of renal function with treatment. None of the 22 relapses met the criteria for severe disease.


      The use of cyclophosphamide and glucocorticoids for induction and methotrexate for maintaining remission is an effective and well-tolerated therapeutic approach in patients with active Wegener’s granulomatosis.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fauci A.
        • Haynes B.
        • Katz P.
        • Wolff S.
        Wegener’s granulomatosis.
        Ann Intern Med. 1983; 98: 76-85
        • Hoffman G.S.
        • Kerr G.S.
        • Leavitt R.Y.
        • et al.
        Wegener granulomatosis.
        Ann Intern Med. 1992; 116: 488-494
        • Langford C.A.
        • Talar-Williams C.
        • Barron K.S.
        • Sneller M.C.
        A staged approach to the treatment of Wegener’s granulomatosis.
        Arthritis Rheum. 1999; 42: 2666-2673
        • Leavitt R.Y.
        • Fauci A.S.
        • Bloch D.A.
        • et al.
        The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis.
        Arthritis Rheum. 1990; 33: 1101-1107
        • Sneller M.C.
        • Hoffman G.S.
        • Talar-Williams C.
        • et al.
        An analysis of forty-two Wegener’s granulomatosis patients treated with methotrexate and prednisone.
        Arthritis Rheum. 1995; 38: 608-613
        • American College of Rheumatology Task Force on Osteoporosis Guidelines
        Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.
        Arthritis Rheum. 1996; 39: 1791-1801
        • Adachi J.D.
        • Bensen W.G.
        • Brown J.
        • et al.
        Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
        N Engl J Med. 1997; 337: 382-387
        • Kerr G.S.
        • Fleisher T.A.
        • Hallahan C.W.
        • et al.
        Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis.
        Arthritis Rheum. 1993; 36: 365-371
        • Kaplan E.
        • Meier P.
        Non-parametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Reinhold-Keller E.
        • Beuge N.
        • Latza U.
        • et al.
        An interdisciplinary approach to the care of patients with Wegener’s granulomatosis.
        Arthritis Rheum. 2000; 43: 1021-1032
        • Guillevin L.
        • Cordier J.F.
        • Lhote F.
        • et al.
        A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis.
        Arthritis Rheum. 1997; 40: 2187-2198
        • Talar-Williams C.
        • Hijazi Y.M.
        • Walther M.M.
        • et al.
        Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.
        Ann Intern Med. 1996; 124: 477-484
        • Cotch M.F.
        • Hoffman G.S.
        • Yerg D.E.
        • et al.
        The epidemiology of We-gener’s granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.
        Arthritis Rheum. 1996; 39: 87-92
        • Reinhold-Keller E.
        • Fink C.O.E.
        • Herlyn K.
        • et al.
        High rate of renal relapse in 71 patients with Wegener’s granulomatosis under maintenance of remission with low-dose methotrexate.
        Arthritis Care Res. 2002; 47: 326-332
        • Jayne D.
        Update on the European Vasculitis Study Group trials.
        Curr Opin Rheumatol. 2001; 13: 48-55